Crisnatol mesylate: Phase I dose escalation by extending infusion duration


Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity. A phase I study with an unconventional escalation scheme was developed using a constant drug infusion rate (mg/m2/hr) and prolonging the infusion duration from 6 to 96 hours. Sixty-five patients received crisnatol at doses from 18 mg/m2 in 6 hrs to 3400 mg/m2 in 72 hours. The dose-limiting toxicity in two of five patients at 2700 mg/m2 and two of three patients at 3400 mg/m2 was neurologic and consisted of a syndrome of confusion, agitation, and disorientation. Phlebitis mandated the use of a central line. The mean terminal phase half-life (T1/2β ) was 3.3 hours with a total body clearance (CL) of 22.8 L/hr/m2 and a volume of distribution (Vdss) of 53 L/m2. The median steady-state peak plasma concentration (Css) at 2700 mg/m2/72 hours was 2.7 μg/ml and at 3400 mg/m2/72 hours was 3.8 μg/ml. No responses were seen. The maximum tolerated dose (MTD) on this schedule is 2700 mg/m2/72 hours in patients with no liver disease and good performance status.

DOI: 10.1007/BF00194543

4 Figures and Tables


Citations per Year

137 Citations

Semantic Scholar estimates that this publication has 137 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Poplin1991CrisnatolMP, title={Crisnatol mesylate: Phase I dose escalation by extending infusion duration}, author={Elizabeth A. Poplin and Guy G. Chabot and Richard L. Tuttle and Sol Lucas and William A Wargin and Laurence H. Baker}, journal={Investigational New Drugs}, year={1991}, volume={9}, pages={41-47} }